Journal of the American Academy of Dermatology
Volume 58, Issue 4 , Pages 585-591, April 2008

Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients

  • Noël Emile Célestin Schartz, MD, PhD

      Affiliations

    • Department of Dermatology 2, Hôpital Saint Louis AP-HP, Paris, France
    • Corresponding Author InformationReprint requests: Noël Emile Célestin Schartz, MD, PhD, Hôpital Saint Louis, Policlinique de dermatologie, 1, avenue Claude Vellefaux, F – 75475 Paris Cedex 10, France.
    • ,
  • Sylvie Chevret, MD, PhD

      Affiliations

    • Departement de Biostatistique et Informatique Médicale, U444-INSERM, Hôpital Saint Louis AP-HP, Paris, France
    • ,
  • Carolina Paz, MD

      Affiliations

    • Department of Dermatology 2, Hôpital Saint Louis AP-HP, Paris, France
    • ,
  • Delphine Kerob, MD

      Affiliations

    • Department of Dermatology 2, Hôpital Saint Louis AP-HP, Paris, France
    • ,
  • Olivier Verola, MD

      Affiliations

    • Laboratory of Pathology, ERM0220 INSERM, Hôpital Saint Louis AP-HP, Paris, France
    • ,
  • Patrice Morel, MD

      Affiliations

    • Department of Dermatology 2, Hôpital Saint Louis AP-HP, Paris, France
    • ,
  • Céleste Lebbé, MD, PhD

      Affiliations

    • Department of Dermatology 2, Hôpital Saint Louis AP-HP, Paris, France

Accepted 2 November 2007. published online 10 December 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by a grant-in-aid from 3M Pharmaceuticals.

 Conflicts of interest: None declared.

PII: S0190-9622(07)02281-5

doi:10.1016/j.jaad.2007.11.005

Journal of the American Academy of Dermatology
Volume 58, Issue 4 , Pages 585-591, April 2008

Article Tools

* Image Usage & Resolution